Profund Advisors LLC Vertex Pharmaceuticals Inc Transaction History

Profund Advisors LLC

$2.65 Billion
Q2 2024

A detailed history of Profund Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Profund Advisors LLC holds 29,546 shares of VRTX stock, worth $14 Million. This represents 0.52% of its overall portfolio holdings.

Number of Shares

29,546

Previous 26,352 12.12%

Holding current value

$14 Million

Previous $11 Million 25.72%

% of portfolio

0.52%

Previous 0.44%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $1.25 Million - $1.55 Million	3,194 Added 12.12%	29,546 $13.8 Million
Q1 2024 May 08, 2024	SELL	$407.69 - $446.08 $705,303 - $771,718	-1,730 Reduced 6.16%	26,352 $11 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $1.2 Million - $1.44 Million	3,495 Added 14.21%	28,082 $11.4 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $1.57 Million - $1.69 Million	4,653 Added 23.34%	24,587 $8.55 Million
Q2 2023 Aug 10, 2023	BUY	$314.42 - $351.91 $304,044 - $340,296	967 Added 5.1%	19,934 $7.01 Million
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $6.32 Million - $7.2 Million	-22,299 Reduced 54.04%	18,967 $5.98 Million
Q4 2022 Feb 02, 2023	SELL	$285.76 - $321.48 $5,143 - $5,786	-18 Reduced 0.04%	41,266 $11.9 Million
Q3 2022 Nov 04, 2022	SELL	$273.83 - $305.53 $552,588 - $616,559	-2,018 Reduced 4.66%	41,284 $12 Million
Q2 2022 Aug 01, 2022	SELL	$234.96 - $292.55 $1.36 Million - $1.7 Million	-5,796 Reduced 11.8%	43,302 $12.2 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $2.11 Million - $2.48 Million	-9,510 Reduced 16.23%	49,098 $12.8 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $1.52 Million - $1.92 Million	-8,612 Reduced 12.81%	58,608 $12.9 Million
Q3 2021 Nov 12, 2021	BUY	$181.39 - $202.99 $6,711 - $7,510	37 Added 0.06%	67,220 $12.2 Million
Q2 2021 Aug 12, 2021	SELL	$187.49 - $221.1 $413,602 - $487,746	-2,206 Reduced 3.18%	67,183 $13.5 Million
Q1 2021 May 14, 2021	SELL	$207.02 - $241.31 $411,969 - $480,206	-1,990 Reduced 2.79%	69,389 $14.9 Million
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $1.08 Million - $1.44 Million	5,230 Added 7.91%	71,379 $16.9 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $2.17 Million - $2.58 Million	-8,501 Reduced 11.39%	66,149 $18 Million
Q2 2020 Aug 03, 2020	BUY	$225.48 - $295.8 $2.21 Million - $2.89 Million	9,783 Added 15.08%	74,650 $21.7 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $4.21 Million - $5.23 Million	-21,092 Reduced 24.54%	64,867 $15.4 Million
Q4 2019 Feb 18, 2020	BUY	$166.71 - $223.91 $1.45 Million - $1.95 Million	8,698 Added 11.26%	85,959 $18.8 Million
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $674,727 - $759,398	-4,059 Reduced 4.99%	77,261 $13.1 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $1.05 Million - $1.22 Million	-6,390 Reduced 7.29%	81,320 $14.9 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $219,725 - $261,287	1,342 Added 1.55%	87,710 $16.1 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $3.17 Million - $4.01 Million	-20,840 Reduced 19.44%	86,368 $14.3 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $1.58 Million - $1.82 Million	9,424 Added 9.64%	107,208 $20.7 Million
Q2 2018 Aug 13, 2018	SELL	$145.72 - $169.96 $677,306 - $789,974	-4,648 Reduced 4.54%	97,784 $16.6 Million
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $1.13 Million - $1.33 Million	-7,484 Reduced 6.81%	102,432 $16.7 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $1.52 Million - $1.73 Million	-11,097 Reduced 9.17%	109,916 $16.5 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $1.43 Million - $1.57 Million	9,680 Added 8.69%	121,013 $18.4 Million
Q2 2017 Aug 11, 2017	BUY	N/A	111,333	111,333 $14.3 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Vertex Pharmaceuticals Inc Transaction History